Literature DB >> 27562445

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.

Jorge J Castillo1, Joshua N Gustine1, Kirsten Meid1, Toni Dubeau1, Guang Yang1, Lian Xu1, Zachary R Hunter1, Steven P Treon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27562445     DOI： 10.1080/10428194.2016.1222380

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

Review 1.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 2.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.

Authors:  Merrie Mosedale; Yanwei Cai; John Scott Eaddy; Robert W Corty; Manisha Nautiyal; Paul B Watkins; William Valdar
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

Review 4.  What is new in the treatment of Waldenstrom macroglobulinemia?

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Leukemia       Date:  2019-10-07       Impact factor: 11.528

5.  Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Authors:  Cécile Tomowiak; Stéphanie Poulain; Charles Herbaux; Aurore Perrot; Béatrice Mahé; Pierre Morel; Thérèse Aurran; Olivier Tournilhac; Stéphane Leprêtre; Souad Assaad; Bruno Villemagne; Olivier Casasnovas; Delphine Nollet; Damien Roos-Weil; Sylvie Chevret; Véronique Leblond
Journal:  Blood Adv       Date:  2021-05-11

Review 6.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

Review 7.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

8.  Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome.

Authors:  Mario Ojeda-Uribe; Valérie Rimelen; Cathérine Marzullo
Journal:  J Blood Med       Date:  2020-02-13

Review 9.  Waldenström macroglobulinemia treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-01       Impact factor: 11.037

10.  Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.

Authors:  M D'Aveni-Piney; M Divoux; H Busby-Venner; M Muller; J Broséus; P Feugier
Journal:  J Med Case Rep       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.